R207910

From Wikipedia, the free encyclopedia

R207910
IUPAC name (1R,2R)-1-(6-bromo-2-methoxyquinolin-3-yl)- 4-(dimethylamino)-2-

(3-fluorophenyl)-1-phenylbutan-2-ol
Other names AIDS222089
Identifiers
CAS number [654653-81-3]
PubChem 5746640
MeSH R207910
Properties
Molecular formula C28H28BrFN2O2
Molar mass 523.437 g/mol
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

R207910 (also known as TMC207) is an experimental diarylquinoline anti-tuberculosis drug, which was discovered by Koen Andries and his team at Janssen Pharmaceutica[1][2]. It was described for the first time in 2004 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting Late-Breaker Session, after the drug had been in development for over 7 years[3].

[edit] Mode Of Action

R207910 affects the proton pump for ATP synthase, which is unlike other quinolones, whose target is DNA gyrase.[4]

[edit] References

  1. ^ Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27
  2. ^ de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738. 
  3. ^ In Search of New Cures for Tuberculosis
  4. ^ Joanne Kotz, Targeting tuberculosis, Nature Chemical Biology, Published online: 8 February 2005 (doi: 10.1038/nchembio002)

[edit] See also

Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Languages